Groen Eric 4
4 · Rani Therapeutics Holdings, Inc. · Filed Dec 19, 2023
Insider Transaction Report
Form 4
Groen Eric
General Counsel
Transactions
- Award
Stock Option (Right to Buy)
2023-12-16+54,167→ 54,167 totalExercise: $2.84Exp: 2031-07-28→ Class A Common Stock (54,167 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−171,500→ 34,300 totalExercise: $5.44Exp: 2033-03-26→ Class A Common Stock (171,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−43,400→ 31,000 totalExercise: $13.21Exp: 2032-03-21→ Class A Common Stock (43,400 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−54,167→ 75,833 totalExercise: $11.00Exp: 2031-07-28→ Class A Common Stock (54,167 underlying) - Award
Stock Option (Right to Buy)
2023-12-16+171,500→ 171,500 totalExercise: $2.84Exp: 2033-03-26→ Class A Common Stock (171,500 underlying) - Award
Stock Option (Right to Buy)
2023-12-16+43,400→ 43,400 totalExercise: $2.84Exp: 2032-03-21→ Class A Common Stock (43,400 underlying)
Footnotes (5)
- [F1]The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023.
- [F2]The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date.
- [F3]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
- [F4]The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.
- [F5]The shares subject to the option vest as follows: 25% of the shares subject to the option vest on July 29, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years.